MTNR1B and type 2 diabetes mellitus: Further pharmacogenetic and functional studies to elucidate the exact effects of MTNR1B variants on repaglinide therapeutic efficacy are necessary to lay the foundation for tailoring of a more precise therapy for T2DM.